CAS: 141430-65-1; N-(2-((4-Hydroxyphenyl)Amino)Pyridin-3-yl)-4-Methoxybenzenesulfonamide

该化合物是一种化学化合物,其结构复杂,包括一个磺酰胺组,一个甲基氧组和附属于一个环的氨基组.该化合物通常具有与磺酰胺有关的特性,例如潜在的抗菌活性,尽管其具体的生物活动可能不同.氢氧联苯和丙烯基母体的存在表明,它可能从事氢联结和欧元互动,从而影响其溶性和再活性.在稳定性方面,磺酰胺一般在标准条件下稳定,但可能对强酸或碱敏感.这种化合物可能具有医学化学特性,特别是针对特定生物路径的药物的研制过程中,因此,应观测到所有化学物质,适当处理和安全防范措施.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号78750-68-2 4-[(3-aminopyri... | CAS号98-68-0 对甲氧基苯磺酰氯 | CAS号5470-18-8 2-氯-3-硝基吡啶 | CAS号123-30-8 对氨基苯酚 | CAS号78750-61-5 Phenol, 4-[(3-n...

合成工艺路线路线简述

    4-((3-Nitropyridin-2-yl)Amino)Phenol置于吡啶,氢气体系中,化学反应生成N-[2-[(4-羟基苯基)氨基]-3-吡啶基]-4-甲氧基苯磺酰胺
    参考文献:新型磺胺类药物作为潜在的全身活性抗肿瘤药.
    标题:新型磺胺类药物作为潜在的全身活性抗肿瘤药.
    摘要:
    Doi:10.1021/jm00091A018

    海关参考信息

    专利信息


    专利号:WO-2017100796-A1
    优先权日:2015-12-11
    标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
    发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
    权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
    摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

    专利号:US-2017283878-A1
    优先权日:2015-12-11
    标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
    发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
    权利人:ACADEMIA SINICA
    摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

    专利号:US-2023202980-A1
    优先权日:2019-08-30
    标题:N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer
    发明人:RADHAKRISHNAN SRIDHAR; TENEN DANIEL G; LIU BEE HUI; VU LE KIM ANH; GO MEI LIN; CHAI LI; GAO CHONG; KAMAL AHMED; SUNKARI SATISH; AYINAMPUDI VENKATA SUBBARAO; SYED RIYAZ; LIU MIAO
    权利人:NAT UNIV SINGAPORE; THE BRIGHAM AND WOMEN’S HOSPITAL INC; INDIAN INSTITUTE OF CHEMICAL TECH
    摘要:Provided herein are N-(2-aminophenyl)-prop-2-enamide derivatives, such as those of Formula (I), methods for the synthesis thereof, and uses thereof in the treatment of cancer, such as SALL4-expressing cancer, in a cell or subject in need thereof.

    专利号:US-2023266302-A1
    优先权日:2020-07-24
    标 题:Synthesis and use of n-benzyl sulfonamides
    发明人:LAMAR ANGUS A; SHEAFF ROBERT J
    权利人:THE UNIV OF TULSA
    摘要:Disclosed is a method for preparing N-benzyl sulfonamides. Also disclosed is a composition for treating cancer. The composition includes a N-benzyl sulfonamide and a metabolic inhibitor. Also disclosed is a method for determining the impact on cell ATP levels of a composition containing a N-benzyl sulfonamide with or without a metabolic inhibitor.

    专利号:US-12180228-B2
    优先权日:2019-06-05
    标题:Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
    发明人:MOVASSAGHI MOHAMMAD; OLSSON CHASE ROBERT; SCOTT TONY Z; CHEAH JAIME; PAYETTE JOSHUA NATHANIEL
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.

    专利号:US-2021329919-A9
    优先权日:2019-07-01
    标 题:Synthesis and anti-cancer activity of communesin alkaloids
    发明人:MOVASSAGHI MOHAMMAD; POMPEO MATTHEW M; CHEAH JAIME
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:Described herein are compounds of Formula (I):and salts, tautomers, and stereoisomers thereof. Methods of making the compounds, salts, tautomers, and stereoisomers are also described. Further described herein are composition, kits, methods, and uses involving the compounds, salts, tautomers, and stereoisomers. The methods include methods of treating and preventing diseases (e.g., cancers) in subjects (e.g., humans).
    上海泽涵生物医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zehanbiopharma.com
    电话: 021-61350663 13052117465👤
    📞上海泽涵生物医药科技有限公司 ⚠️参考联系方式

    销售电话:021-61350663 13052117465
    邮箱:sales@zehanbiopharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    常州欣宜晨药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.xycpharm.com
    企业联系电话:0519-85566998👤
    📞常州欣宜晨药业有限公司 ⚠️参考联系方式
    联系人:徐经理
    电话:0519-85566998
    手机:18502571086
    传真:0519-85566998
    邮箱:xycpharm@163.com
    通信地址: 江苏省常州市天宁区劳动东路388号
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省常州市天宁区劳动东路388号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Galmarini CM. ABT-751 (Abbott). Curr Opin Investig Drugs. 2005 Jun;6(6):623-30. 22(2):945. doi: 10.3390/ijms22020945.
    3: Luo Y, Hradil VP, Frost DJ, Rosenberg SH, Gordon GB, Morgan SJ, Gagne GD, Cox BF, Tahir SK, Fox GB. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anticancer Drugs. 2009 Jul;20(6):483-92. doi: 10.1097/CAD.0b013e32832c0acf. Therapeutic Advances in Childhood Leukemia/Lymphoma Consortium. ABT-751 in relapsed childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012 Oct;34(7):583-4. doi: 10.1097/MPH.0b013e3182532446.
    311:88-98. doi: 10.1016/j.taap.2016.09.021. Epub 2016 Sep 24. 54(1):47-54. doi: 10.1002/pbc.22267.

    合成参考文献


    参考文献:10.1007/s00280-004-0807-0
    摘要:Segreti JA, Polakowski JS, Koch KA, Marsh KC, Bauch JL, Rosenberg SH, Sham HL, Cox BF, Reinhart GA. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol. 2004 Sep;54(3):273–81. doi: 10.1007/s00280-004-0807-0.
    摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知